Estimation of the relative antiinflammatory efficacies of six commercial preparations of Harpagophytum procumbens (Devil's Claw).
The current work compared the relative efficacies of six commercial formulations of H. procumbens. Each formulation was assayed for the content of harpagoside (1), harpagide (2), verbascoside (3) and 8-O-p-coumaroyl harpagide (4) and, based on the recommended dosages, the total daily amounts were determined and used to establish anti-/proinflammatory (A/P) factors. The formulations were compared using ex vivo porcine skin for their activities towards COX-2 by Western blotting. The results showed great variation in the amounts of compounds 1-4 within the six formulations examined. The relative proportions of 1-4 also varied widely between the products and this inconsistency was reflected in the A/P factors, which correlated with the COX-2 expression (R(2) = 0.9496). Although the data support the beneficial antiinflammatory effects from the use of some of the brands tested, others would appear potentially to exacerbate inflammation. To conclude, a ratio based upon the amount and relative proportions of anti- and proinflammatory compounds can be used to predict relative antiinflammatory properties. Also, with access to a diversity of ostensibly similar commercial products, the patient may experience varying therapeutic responses. Finally, current pharmacopoeia monographs, which are generally concerned with a minimum harpagoside content, are inadequate for ensuring the quality of products based on H. procumbens.
Ouitas
Nassima Abdelouahab
NA
Welsh School of Pharmacy, Cardiff University, Cardiff CF10 3XF, Wales, UK.
Heard
Charles
C
D000279:Administration, Cutaneous; D000818:Animals; D000893:Anti-Inflammatory Agents / Q000008:administration & dosage / Q000494:pharmacology*; D051546:Cyclooxygenase 2 / Q000378:metabolism; D004305:Dose-Response Relationship, Drug; D005960:Glucosides / Q000494:pharmacology; D006027:Glycosides / Q000494:pharmacology; D031684:Harpagophytum / Q000737:chemistry*; D066298:In Vitro Techniques; D057889:Iridoid Glycosides; D010636:Phenols / Q000494:pharmacology; D008517:Phytotherapy; D010936:Plant Extracts / Q000008:administration & dosage / Q000494:pharmacology*; D011714:Pyrans / Q000494:pharmacology; D012867:Skin / Q000187:drug effects*; D012869:Skin Absorption; D013552:Swine; D059808:Polyphenols
D000893:Anti-Inflammatory Agents; D051546:Cyclooxygenase 2; D005960:Glucosides; D006027:Glycosides; D057889:Iridoid Glycosides; D010636:Phenols; D010936:Plant Extracts; D011714:Pyrans; C058956:acteoside; D059808:Polyphenols; C033249:harpagoside; C033250:harpagide